LT2892535T - Adjuvantinis vėžio gydymo būdas - Google Patents

Adjuvantinis vėžio gydymo būdas

Info

Publication number
LT2892535T
LT2892535T LTEPPCT/US2013/057432T LT13057432T LT2892535T LT 2892535 T LT2892535 T LT 2892535T LT 13057432 T LT13057432 T LT 13057432T LT 2892535 T LT2892535 T LT 2892535T
Authority
LT
Lithuania
Prior art keywords
cancer treatment
adjuvant cancer
adjuvant
treatment
cancer
Prior art date
Application number
LTEPPCT/US2013/057432T
Other languages
English (en)
Lithuanian (lt)
Inventor
Sylvie Laquerre
Peter F. Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2892535(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2892535T publication Critical patent/LT2892535T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
LTEPPCT/US2013/057432T 2012-09-04 2013-08-30 Adjuvantinis vėžio gydymo būdas LT2892535T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
LT2892535T true LT2892535T (lt) 2021-12-10

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2013/057432T LT2892535T (lt) 2012-09-04 2013-08-30 Adjuvantinis vėžio gydymo būdas

Country Status (20)

Country Link
US (6) US20150216868A1 (enExample)
EP (2) EP2892535B1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN107308164A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2892535T (lt) 2012-09-04 2021-12-10 Novartis Ag Adjuvantinis vėžio gydymo būdas
JP6571665B2 (ja) 2013-12-28 2019-09-04 ガーダント ヘルス， インコーポレイテッド 遺伝的バリアントを検出するための方法およびシステム
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
ES2952265T3 (es) * 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4073102A4 (en) * 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (en) 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
CN105288630A (zh) * 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2745479T3 (es) * 2009-10-16 2020-03-02 Novartis Ag Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
LT2892535T (lt) 2012-09-04 2021-12-10 Novartis Ag Adjuvantinis vėžio gydymo būdas

Also Published As

Publication number Publication date
HRP20211817T1 (hr) 2022-03-04
DK2892535T3 (da) 2022-01-03
US10869869B2 (en) 2020-12-22
ES2900825T3 (es) 2022-03-18
US20180338979A1 (en) 2018-11-29
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
CA2882437A1 (en) 2014-03-13
US20200054641A1 (en) 2020-02-20
JP6511117B2 (ja) 2019-05-15
HUE056646T2 (hu) 2022-02-28
SI2892535T1 (sl) 2022-01-31
BR112015004578A2 (pt) 2017-07-04
KR102134585B1 (ko) 2020-07-17
PT2892535T (pt) 2021-12-15
JP2018058859A (ja) 2018-04-12
CY1124812T1 (el) 2022-11-25
JP2015527374A (ja) 2015-09-17
JP2019142899A (ja) 2019-08-29
EP2892535B1 (en) 2021-09-22
PL2892535T3 (pl) 2022-01-31
CN104582706A (zh) 2015-04-29
KR20150047619A (ko) 2015-05-04
US20170202842A1 (en) 2017-07-20
US20230330091A1 (en) 2023-10-19
RU2640180C2 (ru) 2017-12-26
EP2892535A4 (en) 2016-04-13
EP3981408A1 (en) 2022-04-13
CN107308164A (zh) 2017-11-03
AU2016244279B2 (en) 2018-01-04
WO2014039375A1 (en) 2014-03-13
AU2013313050A1 (en) 2015-03-26
RU2015105821A (ru) 2016-10-20
US20210060021A1 (en) 2021-03-04
JP6684941B2 (ja) 2020-04-22
AU2016244279A1 (en) 2016-11-03
US20150216868A1 (en) 2015-08-06
HK1206642A1 (en) 2016-01-15
IN2015KN00449A (enExample) 2015-07-17

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL237791A0 (en) A method for treating cancer
SG11201503893RA (en) Method of treating cancer
EP2760452A4 (en) METHODS OF TREATING CANCER
IL237558A0 (en) Methods for treating locally advanced breast cancer
IL232890A0 (en) Immunogenic therapy for cancer
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
IL228430A0 (en) Cancer treatment
LT2892535T (lt) Adjuvantinis vėžio gydymo būdas
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201208296D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
AU2012905667A0 (en) Vaccines for treatment of cancer
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment